John Millar, Division of Translational Medicine and Human Genetics and Director of the Metabolic Tracer Resource in the Institute of Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania

The effect of anacetrapib on apolipoprotein (apo) B metabolism

John Millar's research interests focus on studying the mechanisms responsible for changes in lipid and lipoprotein metabolism in response to novel ... Tovább

Workshop: Saturday, May 26, 2012, 15.00 – 16.30

ARTERIAL WALL AND ATHEROSCLEROSIS: CELLULAR AND HUMORAL FACTORS
Bioactive compounds and inflammation in the arterial wall

 ... Tovább

This educational symposium, moderated by Prof. Alberico Catapano, Italy will discuss the unmet medical needs in patients with severe FH and examine the role of over-secretion of apolipoprotein (apo) B-100-containing lipoproteins in increasing the risk of coronary artery disease (CAD). The potential of a new class of agents – the antisense oligonucleotides – in the treatment of patients with severe disease who are unable to achieve treatment ...

In this educational symposium, chaired by Prof. Alberico Catapano, University of Milan, Italy, experts will review current approaches for the management of cardiometabolic risk. The symposium will discuss recent evidence for a novel statin, pitavastatin, in addressing the clinical challenges of managing dyslipidaemia in this high-risk population.
 ...